Search the Newsreel

Vertex Pharmaceuticals (VRTX) Could Be 8% Undervalued Following Raised 2026 Guidance

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Vertex Pharmaceuticals (VRTX) has drawn fresh attention after reporting second quarter 2026 results, raising full year revenue guidance to US$13.1b to US$13.2b, and completing …

Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says

Vertex Pharmaceuticals (VRTX) has multiple potential catalysts coming from its portfolio that provide a net positive risk-reward profile for the company, RBC Capital Markets said in a Wednesday note.The company is expected to present results from its phase 1 study of VX-828 in Silver …

5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q2 Earnings Call

5 Insightful Analyst Questions From Vertex Pharmaceuticals's Q2 Earnings Call Vertex Pharmaceuticals' second quarter reflected strong commercial momentum, with management highlighting the performance of its cystic fibrosis (CF) portfolio and accelerating uptake of newer products like CASGEVY and JOURNAVX. CEO Reshma Kewalramani attributed revenue …

Vertex Pharmaceuticals Rose 7% Today. Here’s Where the Stock Is Headed in 2026

Vertex Stock Jumps 5.9% as Rival Cystic Fibrosis Drug Fails

This article first appeared on GuruFocus. Vertex Pharmaceuticals (NASDAQ:VRTX), the biotech king of cystic fibrosis, jumped approximately 5.9% in Monday's regular session after a rival drug stumbled. Sionna Therapeutics said SION-719 missed the key activity endpoint in a Phase 2a trial when added to …

Vertex Pharmaceuticals (VRTX) Is Up 5.4% After Raising 2026 Revenue Guidance And Expanding Its Pipeline - Has The Bull Case Changed?

Vertex Pharmaceuticals recently reported second-quarter 2026 results, with revenue rising to US$3,333.9 million and net income reaching US$1,099.8 million, and raised its full-year 2026 revenue guidance to US$13.10–US$13.20 billion. At the same time, a new collaboration with AbCellera on multispecific T‑cell engagers and a …

Por que as ações da Vertex Pharmaceuticals disparam hoje? - Investing.com Brasil

Ação da Vertex Pharmaceuticals atinge máxima histórica de US$ 539,99 - Investing.com Brasil

Why Vertex Pharma Popped, As A Key Rival Plummeted 90%

Vertex stock surged Monday after its competitor, Sionna Therapeutics, missed the mark for its highly anticipated cystic fibrosis treatment. Continue Reading

Vertex Pharmaceuticals Seen Well Positioned Ahead of Pipeline Catalysts, UBS Says

Vertex Pharmaceuticals (VRTX) remains well positioned heading into the second half of 2026 as severa PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have …

VRTX Q2 Earnings Call Highlights Launch Momentum & Higher Outlook

Vertex Pharmaceuticals Incorporated VRTX raised its 2026 revenue outlook as cystic fibrosis growth and contributions from newer products accelerated. Management framed 2026 as an execution year, with commercial scaling, a near-term renal launch and the pending Crinetics acquisition shaping diversification. VRTX Raises Outlook as …

Vertex Pharmaceuticals’ Q2 Earnings Call Confirmed an $8.8 Billion Bet. Here’s What That Means for the Stock

Vertex (VRTX) Reports Q2 Earnings: What Key Metrics Have to Say

For the quarter ended June 2026, Vertex Pharmaceuticals (VRTX) reported revenue of $3.33 billion, up 12.5% over the same period last year. EPS came in at $4.73, compared to $4.52 in the year-ago quarter. The reported revenue represents a surprise of +3.32% over the …

Vertex Pharmaceuticals (NASDAQ:VRTX) Beats Q2 CY2026 Sales Expectations, Full-Year Outlook Slightly Exceeds Expectations

Vertex Pharmaceuticals (NASDAQ:VRTX) Beats Q2 CY2026 Sales Expectations, Full-Year Outlook Slightly Exceeds Expectations Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) announced better-than-expected revenue in Q2 CY2026, with sales up 12.5% year on year to $3.33 billion. The company's full-year revenue guidance of $13.15 billion at the …

Vertex Reports Second Quarter 2026 Financial Results

— Total revenue of $3.33 billion, a 12% increase compared to second quarter 2025 — — Raising full-year revenue guidance to $13.1 billion to $13.2 billion — — Continued progress across research and development pipeline; povetacicept PDUFA date November 30th — — Entered into …

Vertex Pharmaceuticals (VRTX) Stock Looks Like A Bargain At This Price

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Vertex Pharmaceuticals has delivered a 145.1% return over the past five years, yet its current valuation picture is mixed, as a Discounted Cash …

Vertex (VRTX) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates

Wall Street analysts forecast that Vertex Pharmaceuticals (VRTX) will report quarterly earnings of $4.85 per share in its upcoming release, pointing to a year-over-year increase of 7.3%. It is anticipated that revenues will amount to $3.23 billion, exhibiting an increase of 8.8% compared to …

Vertex Pharmaceuticals (VRTX) Exceeds Market Returns: Some Facts to Consider

Vertex Pharmaceuticals (VRTX) ended the recent trading session at $490.39, demonstrating a +2.38% change from the preceding day's closing price. The stock exceeded the S&P 500, which registered a gain of 0.21% for the day. Elsewhere, the Dow gained 1.03%, while the tech-heavy Nasdaq …

Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Over the past month, shares of this drugmaker have …

Vertex Pharmaceuticals (VRTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Vertex Pharmaceuticals (VRTX) closed at $472.57 in the latest trading session, marking a -1.96% move from the prior day. The stock fell short of the S&P 500, which registered a loss of 0.14% for the day. On the other hand, the Dow registered a …

How FDA’s Pediatric Expansion of Casgevy at Vertex Pharmaceuticals (VRTX) Has Changed Its Investment Story

Earlier this month, the FDA expanded approval of Vertex Pharmaceuticals' gene therapy Casgevy (exagamglogene autotemcel) to children aged 2 and older with sickle cell disease and transfusion-dependent thalassemia, following strong efficacy signals in two small pediatric trials. This milestone meaningfully widens access to a …